Process for the production of unfused protein in e. coli
CA 2030947 A1 · Owner: Novartis Ag · Inventors: Schmitz, Albert; Marki, Walter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
4-17838/=, Novel process for the production of unfused protein in E. coli Abstract of the Disclosure, A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.